Reinhard Hohlfeld

Reinhard Hohlfeld's AcademicInfluence.com Rankings

Reinhard Hohlfeld

Physics

#4368

World Rank

#6017

Historical Rank

Particle Physics

#182

World Rank

#195

Historical Rank

physics Degrees

Download Badge

Physics

Why Is Reinhard Hohlfeld Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Reinhard Hohlfeld's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. (2010) (2329)
Activated Human T Cells, B Cells, and Monocytes Produce Brain-derived Neurotrophic Factor In Vitro and in Inflammatory Brain Lesions: A Neuroprotective Role of Inflammation? (1999) (1008)
Clonal Expansions of Cd8+ T Cells Dominate the T Cell Infiltrate in Active Multiple Sclerosis Lesions as Shown by Micromanipulation and Single Cell Polymerase Chain Reaction (2000) (940)
Polymyositis and dermatomyositis (2003) (718)
Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice (2017) (556)
MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. (2009) (545)
Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. (2006) (498)
BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma (2005) (445)
BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? (2002) (402)
Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. (1997) (397)
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring (2007) (391)
Neurofascin as a novel target for autoantibody-mediated axonal injury (2007) (382)
Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. (2004) (354)
Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. (2000) (311)
Mechanisms of Disease: aquaporin-4 antibodies in neuromyelitis optica (2008) (308)
Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis (2011) (286)
B lineage cells in the inflammatory central nervous system environment: Migration, maintenance, local antibody production, and therapeutic modulation (2006) (279)
The immunobiology of muscle. (1994) (276)
Neurotrophic cross‐talk between the nervous and immune systems: Implications for neurological diseases (2003) (272)
Mechanisms of action of glatiramer acetate in multiple sclerosis (2001) (269)
Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab (2011) (265)
Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. (2002) (264)
Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis (2008) (262)
Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: From pipe dreams to (therapeutic) pipelines (2004) (254)
B cells and antibodies in multiple sclerosis pathogenesis and therapy (2012) (245)
Multiple sclerosis (1999) (240)
Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. (1996) (240)
γ-secretase directly sheds the survival receptor BCMA from plasma cells (2015) (231)
Autoimmune human T lymphocytes specific for acetylcholine receptor (1984) (224)
Guidelines on use of anti‐IFN‐β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN‐β antibodies in multiple sclerosis (2005) (218)
Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations (2008) (218)
A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS (2002) (216)
Neurofascin as a target for autoantibodies in peripheral neuropathies (2012) (213)
Antibody to Aquaporin 4 in the Diagnosis of Neuromyelitis Optica (2007) (211)
Multiple sclerosis: T-cell receptor expression in distinct brain regions. (2007) (205)
Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals (2009) (203)
Myasthenia gravis (1983) (201)
Immunobiology of muscle: advances in understanding an immunological microenvironment. (2005) (192)
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension (2018) (190)
Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis (2008) (188)
Human myoblasts as antigen presenting cells (1991) (180)
NMO-IgG in the diagnosis of neuromyelitis optica (2007) (178)
Neuro-immune crosstalk in CNS diseases (2009) (175)
Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis (2016) (175)
The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis (2000) (167)
Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. (2008) (164)
Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. (2000) (164)
Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein. (1999) (164)
The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research (2016) (161)
Histopathology and clinical course of MOG-antibody-associated encephalomyelitis (2015) (153)
Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society (2016) (153)
Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. (2004) (150)
The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets (2016) (149)
Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS (2011) (146)
The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis (2006) (142)
T cell receptor repertoire in polymyositis: clonal expansion of autoaggressive CD8+ T cells (1995) (141)
Polymyositis Mediated by T Lymphocytes That Express the γ/δ Receptor (1991) (138)
Corticosteroids for myasthenia gravis. (2005) (137)
Cytotoxic mechanisms in inflammatory myopathies. Co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells. (1997) (136)
Glatiramer Acetate in the Treatment of Multiple Sclerosis (2011) (130)
From classic to spontaneous and humanized models of multiple sclerosis: impact on understanding pathogenesis and drug development. (2014) (130)
Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation (2016) (127)
Extracellular Matrix in Multiple Sclerosis Lesions: Fibrillar Collagens, Biglycan and Decorin are Upregulated and Associated with Infiltrating Immune Cells (2010) (127)
Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action (2005) (126)
Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins (2016) (126)
Related B cell clones that populate the CSF and CNS of patients with multiple sclerosis produce CSF immunoglobulin (2011) (124)
Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. (2002) (123)
HLA-DQ BETA-CHAIN POLYMORPHISM LINKED TO MYASTHENIA GRAVIS (1986) (120)
Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. (2003) (120)
Features of Human CD3+CD20+ T Cells (2016) (119)
Constitutive and cytokine-induced expression of human leukocyte antigens and cell adhesion molecules by human myotubes. (1993) (119)
CCL19 is constitutively expressed in the CNS, up-regulated in neuroinflammation, active and also inactive multiple sclerosis lesions (2007) (119)
Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells. (2001) (117)
Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. (2005) (116)
Distinction and Temporal Stability of Conformational Epitopes on Myelin Oligodendrocyte Glycoprotein Recognized by Patients with Different Inflammatory Central Nervous System Diseases (2013) (116)
Stimulation of the neurotrophin receptor TrkB on astrocytes drives nitric oxide production and neurodegeneration (2012) (115)
Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment. (2012) (114)
The emerging role of microRNAs in multiple sclerosis (2011) (114)
Clonal tracking of autoaggressive T cells in polymyositis by combining laser microdissection, single-cell PCR, and CDR3-spectratype analysis (2003) (114)
Reversible encephalopathy with cerebral vasospasm in a Guillain-Barre syndrome patient treated with intravenous immunoglobulin (1996) (114)
The fine specificity of the myelin oligodendrocyte glycoprotein autoantibody response in patients with multiple sclerosis and normal healthy controls (2001) (114)
Long-term effects of fingolimod in multiple sclerosis (2015) (113)
Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein (2018) (113)
Constitutive and cytokine-induced production of interleukin-6 by human myoblasts. (1994) (113)
Azathioprine toxicity during long‐term immunosuppression of generalized myasthenia gravis (1988) (110)
Distinct responses of monocytes to Toll-like receptor ligands and inflammatory cytokines. (2004) (109)
Immunological update on multiple sclerosis (2001) (109)
Muscle fibers in inflammatory myopathies and cultured myoblasts express the nonclassical major histocompatibility antigen HLA‐G (2000) (109)
Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives (2017) (108)
Dual role of inflammation in CNS disease (2007) (107)
Human astrocytes are only partially competent antigen presenting cells. Possible implications for lesion development in multiple sclerosis. (1994) (106)
Induction of HLA-DR expression on human myoblasts with interferon-gamma. (1990) (106)
Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions. (1998) (104)
Neutralizing antibodies and efficacy of interferon β-1a (2005) (102)
Myasthenia gravis: Reactivation of clinical disease and of automimmune factors after discontinuation of long‐term azathioprine (1985) (101)
Coculture with autologous myotubes of cytotoxic T cells isolated from muscle in inflammatory myopathies (1991) (101)
Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. (2012) (98)
Human T-helper lymphocytes in myasthenia gravis recognize the nicotinic receptor alpha subunit. (1987) (95)
The non-classical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: implications for myoblast transplantation and gene therapy. (2003) (95)
Therapies for multiple sclerosis: translational achievements and outstanding needs. (2013) (94)
Multiple sclerosis. Immunomodulatory effects of human astrocytes on T cells. (1994) (94)
Quantification of Perfusion and Permeability in Multiple Sclerosis: Dynamic Contrast-Enhanced MRI in 3D at 3T (2012) (93)
The Immunoregulator Soluble TACI Is Released by ADAM10 and Reflects B Cell Activation in Autoimmunity (2015) (91)
Immortalization of human T cells by Herpesvirus saimiri. (1995) (91)
THYMIC MYOGENESIS, T‐LYMPHOCYTES AND THE PATHOGENESIS OF MYASTHENIA GRAVIS * (1981) (91)
Intrathecal antibody production against Chlamydia pneumoniae in multiple sclerosis is part of a polyspecific immune response. (2001) (89)
Genetic control of multiple sclerosis: Increased production of lymphotoxin and tumor necrosis factor‐α by HLA‐DR2+ T cells (1995) (88)
Paraneoplastic myasthenia gravis: Detection of anti-MGT30 (titin) antibodies predicts thymic epithelial tumor (1997) (88)
Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS (2016) (87)
CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis (2016) (85)
The role of neurotrophins in muscle under physiological and pathological conditions (2006) (83)
Cellular immune mechanisms in inflammatory myopathies. (1997) (83)
Transplantation of thymic autoimmune microenvironment to severe combined immunodeficiency mice. A new model of myasthenia gravis. (1992) (83)
T-cell-mediated autoimmunity: novel techniques to characterize autoreactive T-cell receptors. (2003) (81)
The role of autoimmune T lymphocytes in the pathogenesis of multiple sclerosis (1995) (80)
De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate (2011) (80)
Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid (2015) (79)
Multiple sclerosis therapeutics (2009) (79)
Compartmentalization of inflammation in the CNS: A major mechanism driving progressive multiple sclerosis (2008) (78)
Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab‐associated progressive multifocal leukoencephalopathy (2014) (78)
Risks and risk management in modern multiple sclerosis immunotherapeutic treatment (2019) (78)
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. (2021) (76)
Risk-Benefit Assessment of Glatiramer Acetate in Multiple Sclerosis (2001) (76)
Role of B Cells in Multiple Sclerosis and Related Disorders (2020) (73)
Modelling paraneoplastic CNS disease: T-cells specific for the onconeuronal antigen PNMA1 mediate autoimmune encephalomyelitis in the rat. (2004) (73)
Escalating immunotherapy of multiple sclerosis--new aspects and practical application. (2004) (73)
Transformation of human T-cell clones by Herpesvirus saimiri: intact antigen recognition by autonomously growing myelin basic protein-specific T cells. (1993) (72)
Reconstitution of paired T cell receptor α- and β-chains from microdissected single cells of human inflammatory tissues (2006) (71)
Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders (2011) (70)
Mechanism of action of glatiramer acetate in treatment of multiple sclerosis (2007) (69)
Intrathecal antibody (IgG) production against human herpesvirus type 6 occurs in about 20% of multiple sclerosis patients and might be linked to a polyspecific B–cell response (2005) (69)
PML risk stratification using anti-JCV antibody index and L-selectin (2016) (67)
Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter injury (2010) (67)
Intrathecal somatic hypermutation of IgM in multiple sclerosis and neuroinflammation. (2014) (67)
Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. (2007) (67)
Revised McDonald criteria: The persisting importance of cerebrospinal fluid analysis (2011) (65)
Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis (2013) (65)
Encephalitogenic potential of myelin basic protein-specific T cells isolated from normal rhesus macaques. (1997) (65)
Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF (2015) (64)
Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration (2016) (64)
The ups and downs of multiple sclerosis therapeutics (2001) (63)
Myasthenia gravis (1986) (63)
Multiple sclerosis: prospective analysis of TNF-α and 55 kDa TNF receptor in CSF and serum in correlation with clinical and MRI activity (1996) (63)
Early adaptive immune activation detected in monozygotic twins with prodromal multiple sclerosis. (2019) (63)
T-cell heterogeneity in muscle lesions of inclusion body myositis (1998) (63)
Amphipathic segment of the nicotinic receptor alpha subunit contains epitopes recognized by T lymphocytes in myasthenia gravis. (1988) (62)
Intravenous immunoglobulins contain naturally occurring antibodies that mimic antineutrophil cytoplasmic antibodies and activate neutrophils in a TNFalpha-dependent and Fc-receptor-independent way. (2007) (62)
Fingolimod induces neuroprotective factors in human astrocytes (2015) (62)
Autoaggressive myocytotoxic T lymphocytes expressing an unusual gamma/delta T cell receptor (1992) (61)
Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients (2002) (61)
Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab (2009) (61)
Genetic restriction of autoreactive acetylcholine receptor-specific T lymphocytes in myasthenia gravis. (1985) (60)
Unbiased identification of target antigens of CD8+ T cells with combinatorial libraries coding for short peptides (2012) (59)
Multiple sclerosis: comparison of the human T-cell response to S100 beta and myelin basic protein reveals parallels to rat experimental autoimmune panencephalitis. (1997) (57)
Bidirectional growth of the E. coli chromosome. (1973) (57)
["Chronic cerebrospinal venous insufficiency" and multiple sclerosis: critical analysis and first observation in an unselected cohort of MS patients]. (2010) (56)
Humoral autoimmunity in multiple sclerosis (2011) (56)
Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy (2005) (56)
BK virus encephalitis in an immunocompetent patient. (1996) (55)
Late-onset tumor necrosis factor receptor-associated periodic syndrome in multiple sclerosis patients carrying the TNFRSF1A R92Q mutation. (2007) (53)
Neurological autoimmune disease and the trimolecular complex of T‐lymphocytes (1989) (49)
The role of the thymus in myasthenia gravis. (1994) (49)
Target Specificity of an Autoreactive Pathogenic Human γδ-T Cell Receptor in Myositis* (2012) (48)
Guidelines on dermatomyositis – excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology (2016) (48)
The immunopathogenesis of myasthenia gravis. (2008) (47)
Drug Insight: using monoclonal antibodies to treat multiple sclerosis (2005) (46)
Human T cell autoimmunity against myelin basic protein: CD4+ cells recognizing epitopes of the T cell receptor β chain from a myelin basic protein‐specific T cell clone (1993) (46)
Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis (2002) (46)
Neurotrophic cross-talk between the nervous and immune systems: Relevance for repair strategies in multiple sclerosis? (2008) (45)
Molecular mimicry in multiple sclerosis. (2003) (44)
Lysis of myotubes by alloreactive cytotoxic T cells and natural killer cells. Relevance to myoblast transplantation. (1990) (43)
Myasthenia gravis: prototype of the antireceptor autoimmune diseases. (1990) (43)
Expression and Function of Glial Cell Line-Derived Neurotrophic Factor Family Ligands and Their Receptors on Human Immune Cells1 (2005) (43)
First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine (2021) (42)
Expanding spectrum of neurologic manifestations in patients with NLRP3 low-penetrance mutations (2015) (42)
DNA methylation signatures of monozygotic twins clinically discordant for multiple sclerosis (2019) (41)
αβ T-cell receptors from multiple sclerosis brain lesions show MAIT cell–related features (2015) (41)
Molecular pathogenesis of neuroinflammation (2003) (41)
Inclusion Body Myositis (2006) (41)
The recognition, diagnosis and management of cerebral vasculitis: a European survey (2002) (41)
An Autoreactive γδ TCR Derived from a Polymyositis Lesion1 (2002) (40)
T-cell autoimmunity in multiple sclerosis. (1995) (39)
Interferon β-1a in relapsing multiple sclerosis: four-year extension of the European IFNβ-1a Dose-C omparison Study (2004) (37)
Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study (2019) (37)
Autoimmune rat T lymphocytes monospecific for acetylcholine receptors: purification and fine specificity. (1981) (37)
Assessment of Potential Cardiotoxic Side Effects of Mitoxantrone in Patients with Multiple Sclerosis (2005) (35)
Multiple Sclerosis: Clinical Challenges and Controversies (1997) (35)
Reflections on the “intrathymic pathogenesis” of myasthenia gravis (2008) (34)
Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis (2018) (34)
Transcript profiling of different types of multiple sclerosis lesions yields FGF1 as a promoter of remyelination (2014) (34)
Human Plasmacytoid Dendritic Cells Display and Shed B Cell Maturation Antigen upon TLR Engagement (2017) (34)
Cellular mechanisms in inflammatory myopathies. (1993) (33)
Review: Progress in the treatment of myasthenia gravis (2008) (33)
[Multiple sclerosis. Current review of failed and discontinued clinical trials of drug treatment]. (2000) (32)
Identification of circulating MOG-specific B cells in patients with MOG antibodies (2019) (31)
Multiple sclerosis: Human model for EAE? (2009) (31)
Diversity of the anti-T-cell receptor immune response and its implications for T-cell vaccination therapy of multiple sclerosis. (1998) (31)
Immunopathogenesis of multiple sclerosis: MBP and beyond (2002) (31)
Polymyositis mediated by T lymphocytes that express the gamma/delta receptor. (1991) (30)
Familial Mediterranean fever-associated mutation pyrin E148Q as a potential risk factor for multiple sclerosis (2012) (30)
Effector mechanisms in myasthenia gravis: End‐plate function after passive transfer of IgG, Fab, and F(ab′)2 hybrid molecules (1986) (30)
Visualizing context-dependent calcium signaling in encephalitogenic T cells in vivo by two-photon microscopy (2017) (30)
Myasthenia gravis (1991) (30)
Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity (2020) (29)
Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod (2014) (29)
Muscle-derived positive and negative regulators of the immune response (2005) (28)
Experimental myasthenia: Lack of correlation between the autoantibody titer and the reduction of acetylcholine‐controlled ionic channels measured at functioning endplates (1983) (28)
Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study. (2004) (28)
Multiple sclerosis and the TNFRSF1A R92Q mutation (2008) (28)
Multiple Sclerosis: A Comprehensive Text (2008) (28)
Multiple sclerosis–like lesions and type I interferon signature in a patient with RVCL (2014) (27)
Thymoma-associated myasthenia gravis. Transplantation of thymoma and extrathymomal thymic tissue into SCID mice. (1996) (27)
Prospects of Transcript Profiling for mRNAs and MicroRNAs Using Formalin‐Fixed and Paraffin‐Embedded Dissected Autoptic Multiple Sclerosis Lesions (2012) (27)
Future clinical challenges in multiple sclerosis (2011) (26)
Twin study reveals non-heritable immune perturbations in multiple sclerosis (2022) (26)
Expression of 65‐kd heat shock proteins in the inflammatory myopathies (1992) (25)
Immune signatures of prodromal multiple sclerosis in monozygotic twins (2020) (24)
Different aspects of cytokines in the immunopathology of multiple scleroosis (1995) (24)
Molecular pathogenesis of neuroinflammation. (2003) (24)
Therapy of Myasthenia Gravis and Myasthenic Syndromes (2003) (23)
Expression and Function of Glial Cell Line-Derived Neurotrophic Factor Family Ligands and Their Receptors on Human Immune Cells (2005) (23)
Household paired design reduces variance and increases power in multi-city gut microbiome study in multiple sclerosis (2020) (22)
Growth transformation of antigen-specific T cell lines from rhesus monkeys by herpesvirus saimiri. (1997) (22)
Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course (2022) (21)
Myasthenia gravis: Discontinuation of long‐term azathioprine (1988) (21)
Does inflammation stimulate remyelination? (2007) (20)
Inhibitors of tumor necrosis factor-α: Promising agents for the treatment of multiple sclerosis? (1996) (19)
T-lymphocytes in experimental autoimmune myasthenia gravis Isolation of T-helper cell lines (1982) (19)
T cell transformation with Herpesvirus saimiri: a tool for neuroimmunological research (2000) (19)
[Immunogenetics of myasthenia gravis. Significance of HLA-, complement and Cm gene systems for clinical and immunologic parameters]. (2008) (19)
Immunologic factors in primary progressive multiple sclerosis (2004) (19)
Therapeutic Approaches in Multiple Sclerosis (2012) (19)
HLA expression in myoblasts (1991) (18)
Novel approaches for identifying target antigens of autoreactive human B and T cells (2009) (18)
Basic principles of immunotherapy for neurologic diseases. (2003) (18)
B- and T-cell responses in multiple sclerosis: Novel approaches offer new insights (2008) (18)
Communication of CD8+ T cells with mononuclear phagocytes in multiple sclerosis (2019) (17)
Multiple sclerosis: TNFRSF1A, TRAPS and multiple sclerosis (2009) (17)
BDNF and its receptors in human myasthenic thymus: Implications for cell fate in thymic pathology (2008) (17)
Dynamic Contrast-Enhanced Magnetic Resonance Imaging Suggests Normal Perfusion in Normal-Appearing White Matter in Multiple Sclerosis (2016) (17)
Gut Microbiota in Multiple Sclerosis: A Bioreactor Driving Brain Autoimmunity (2016) (17)
TNFRSF1A R92Q MUTATION IN ASSOCIATION WITH A MULTIPLE SCLEROSIS–LIKE DEMYELINATING SYNDROME (2008) (16)
Revised diagnostic criteria for neuromyelitis optica—incorporation of NMO-IgG status (2007) (16)
Ocrelizumab in multiple sclerosis: markers and mechanisms (2017) (16)
Acetylcholine Receptor‐Specific Human T‐Lymphocyte Lines a (1987) (16)
Biomarkers in Multiple Sclerosis (2006) (16)
Multiple sclerosis: longitudinal measurement of interleukin-1 receptor antagonist. (1997) (15)
Differential aspects of cytokines in the immunopathology of multiple sclerosis. (1995) (15)
The role of the gut microbiota in multiple sclerosis (2022) (15)
Features of MOG required for recognition by patients with MOG antibody-associated disorders. (2021) (15)
Autoaggressive Myocytotoxic T Lymphocytes Expressing an Unusual 7 / ~ T Cell Receptor (2003) (15)
Managing Risks with Immune Therapies in Multiple Sclerosis (2019) (15)
Therapeutic strategies in multiple sclerosis. I. Immunotherapy. (1999) (15)
Abundant glutamic acid decarboxylase (GAD)‐reactive B cells in gad‐antibody–associated neurological disorders (2019) (15)
T-cell receptor repertoire of human peripheral CD161hiTRAV1-2+ MAIT cells revealed by next generation sequencing and single cell analysis. (2015) (15)
Cross-reactive T-cell receptors in tumor and paraneoplastic target tissue. (2009) (15)
Immunology of MS (1998) (15)
Update on sporadic inclusion body myositis. (2011) (14)
Mitochondrial DNA Variation and Heteroplasmy in Monozygotic Twins Clinically Discordant for Multiple Sclerosis (2016) (14)
[Revision of McDonald's new diagnostic criteria for multiple sclerosis]. (2006) (14)
Cross-reactivity of a pathogenic autoantibody to a tumor antigen in GABAA receptor encephalitis (2021) (14)
[The effect of combined mitoxantrone and methylprednisolone therapy in primary and secondary progressive multiple sclerosis. An applied study in 65 patients]. (2005) (14)
Revisiting the immunopathogenesis of the inflammatory myopathies (2007) (14)
Myelin failure in multiple sclerosis: Breaking the spell of Notch (2002) (14)
Myogenesis in thymic transplants in the severe combined immunodeficient mouse model of myasthenia gravis. Differentiation of thymic myoid cells into striated muscle cells. (1994) (13)
Cytotoxic T cells go awry in inclusion body myositis. (2016) (13)
Broader Epstein–Barr virus–specific T cell receptor repertoire in patients with multiple sclerosis (2022) (13)
Biologically stressed muscle fibers in sporadic IBM (2000) (13)
Long-Term Efficacy and Safety of Fingolimod (FTY720) in Relapsing-Remitting Multiple Sclerosis (RRMS): Results from the Extension of the Phase III FREEDOMS Study (S41.004) (2012) (13)
Strategies for the modulation of neuroimmunological disease at the level of autoreactive T-lymphocytes (1985) (13)
Immunology of Neuromuscular Disease (1994) (13)
Diagnostic criteria for polymyositis and dermatomyositis (2003) (13)
[Risk stratification of progressive multifocal leukoencephalopathy under natalizumab: recommendations for JC virus serology]. (2011) (13)
Review: ‘Gimme five’: future challenges in multiple sclerosis. ECTRIMS Lecture 2009 (2010) (13)
The use of intravenous immunoglobulins in the treatment of neuromuscular disorders (1996) (12)
Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. (2014) (12)
An expanded parenchymal CD8+ T cell clone in GABAA receptor encephalitis (2020) (12)
Unusual natalizumab-associated progressive multifocal leukoencephalopathy starting in the brainstem (2013) (11)
Type III Systemic Allergic Reaction to Natalizumab. Authors' reply (2008) (11)
An autoreactive gamma delta TCR derived from a polymyositis lesion. (2002) (11)
Facing the urgency of therapies for progressive MS — a Progressive MS Alliance proposal (2021) (11)
Necrotizing myopathy in SJL mice. (1988) (11)
Human T-helper lymphocytes in myasthenia gravis recognize the nicotinic receptor a subunit ( immunoregulation / autoimmune disease / immunotherapy ) (11)
The role of gamma-delta T lymphocytes in inflammatory muscle disease. (1992) (11)
The Glycosylation Site of Myelin Oligodendrocyte Glycoprotein Affects Autoantibody Recognition in a Large Proportion of Patients (2019) (11)
Polymyositis and dermatomyositis. (2003) (11)
Inhibitors of tumor necrosis factor-alpha: promising agents for the treatment of multiple sclerosis? (1996) (11)
Gardener's mydriasis (1992) (11)
Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis. (2016) (11)
Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab “infusion group” (2013) (11)
Neuro-immune crosstalk in CNS diseases. (2010) (10)
Analysis of immunoglobulin and T cell receptor gene rearrangements in the thymus of myasthenia gravis patients (1989) (10)
Multiple sclerosis: Relating MxA transcription to anti-interferon-β-neutralizing antibodies (2007) (10)
Non-specific alterations of craniocervical venous drainage in multiple sclerosis revealed by cardiac-gated phase-contrast MRI (2012) (10)
[Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action]. (2016) (10)
T Cell Receptor Repertoire in Polymyositis : Clonal Expansion of Autoaggressive CD 8 + T Cells (2003) (9)
[Open use of natalizumab. Neutralising antibodies and clinical data]. (2008) (9)
Antigen recognition properties of a Vγ1.3Vδ2-T-cell receptor from a rare variant of polymyositis (2004) (9)
Drug-induced Sweet’s syndrome after mitoxantrone therapy in a patient with multiple sclerosis (2011) (9)
Viability of autoantibody-targets: How to tackle pathogenetic heterogeneity as an obstacle for treatment of multiple sclerosis (2012) (8)
Thirty-one episodes of myelitis and optic neuritis in a woman with neuromyelitis optica and systemic lupus erythematosus. (2010) (8)
Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis (2019) (8)
Double-blind randomized multicenter dose-comparison study of interferon-β-1a (AVONEX): rationale, design and baseline data (2001) (8)
[Pregnancy and immunomodulatory therapy in multiple sclerosis patients]. (2006) (8)
T Cell–Transfer Experimental Autoimmune Encephalomyelitis: Pillar of Multiple Sclerosis and Autoimmunity (2017) (8)
Multiple Sclerosis Therapeutics, 3rd ed (2007) (7)
Epstein-Barr virus-transformed B cells can present acetylcholine receptor to autologous autoreactive T cells. (1986) (7)
Molecular oracles for multiple sclerosis therapy (2010) (7)
How promising is hematopoetic stem cell transplantation in multiple sclerosis? (2002) (7)
B-cells as therapeutic targets in neuro-inflammatory diseases. (2017) (7)
The CSF JCV antibody index for diagnosis of natalizumab-associated PML (2014) (7)
Cytokine networks in multiple sclerosis (1995) (7)
Assessing the quality of life of patients with multiple sclerosis (1997) (7)
[Multiple sclerosis and retroviruses]. (2009) (7)
Multiple Sklerose Chlamydien-Hypothese in der Diskussion (2001) (7)
[Immunotherapies for multiple sclerosis : review and update]. (2015) (7)
Myositis Diagnosis and Management (2002) (6)
Neuromuscular transmission in experimental autoimmune myasthenia gravis (EAMG) (1981) (6)
Anti-titin antibodies are not associated with a specific thymoma histology (2003) (6)
Antiglutamatergic therapy for multiple sclerosis? (2016) (6)
CHAPTER 16 – Principles of Therapeutic Approaches to Autoimmunity (1992) (6)
Ion channels boost axonal injury in multiple sclerosis (2012) (6)
[Antegren (natalizumab). A promising new approach to therapy of multiple sclerosis]. (2002) (6)
Hunting (auto)immune T cells in neuroimmunological diseases. (2003) (6)
Oligodendrocyte myelin glycoprotein as a novel target for pathogenic autoimmunity in the CNS (2020) (6)
['Fatigue' in multiple sclerosis]. (1999) (5)
Expression and role of novel B7 family members in human muscle: implications for the pathogenesis of inflammatory myopathies (2004) (5)
[Update: treatment of multiple sclerosis]. (2009) (5)
[Oral fingolimod in multiple sclerosis: therapeutic modulation of the sphingosine-1-phosphate system]. (2011) (5)
Plasma lipidomics of monozygotic twins discordant for multiple sclerosis (2020) (5)
The prospects for neuroprotection in MS. (2003) (5)
[Therapy of multiple sclerosis with interferon-beta-1b. Educating the patient and managing side-effects]. (1996) (5)
Symptoms Related to Tumor Necrosis Factor Receptor 1-associated Periodic Syndrome, Multiple Sclerosis, and Severe Rheumatoid Arthritis in Patients Carrying the TNF Receptor Superfamily 1A D12E/p.Asp41Glu Mutation (2013) (5)
[Treatment of multiple sclerosis with glatiramer acetate. Current aspects of mechanisms of action, pharmacokinetics, adverse effect profile and clinical studies]. (2002) (4)
Beneficial brain autoimmunity? (2010) (4)
CD20+ T Cells as Pathogenic Players and Therapeutic Targets in MS (2021) (4)
Multiple sclerosis (2016) (4)
Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair (2022) (4)
[Interferon beta-1b for treatment of secondary chronic progressive multiple sclerosis]. (1999) (4)
[Progressive multifocal leukoencephalopathy under natalizumab. Initial possibilities for risk stratification?]. (2011) (4)
Treatment of multiple sclerosis with glatiramer acetate - new information about its mechanisms of action, pharmacokinetics, adverse effects and clinical studies (2002) (4)
[Multiple sclerosis. Chlamydia hypothesis in debate]. (2001) (4)
Permanent Lines of T Lymphocytes Specific for Acetylcholine Receptors: A Clonal Approach to Study the Pathogenesis of Myasthenia Gravis (1984) (4)
Multiple sclerosis: Cladribine—a contentious therapeutic contender for MS (2011) (4)
A bird's-eye view of T cells during natalizumab therapy (2013) (4)
Myasthenia gravis: selective enrichment of antiacetylcholine receptor antibody production in untransformed human B cell cultures (1999) (3)
Intrathecal immune response against Chlamydia pneumoniae in multiple sclerosis (2001) (3)
Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal (2021) (3)
Zero tolerance (to acetylcholine receptor) and ways to overcome it (2010) (3)
[Multiple sclerosis and microbiota. From genome to metagenome?]. (2015) (3)
[Interferon-beta in treatment of relapsing multiple sclerosis]. (1994) (3)
Prejunctional effects of anticholinesterase drugs at the endplate (1981) (3)
Efficacy Outcome Measures of Oral Ponesimod Compared to Teriflunomide in Patients with Relapsing Multiple Sclerosis: Results of the Randomized, Active-Controlled, Double-Blind, Parallel-Group Phase 3 OPTIMUM Study (3972) (2020) (3)
T-cell mediated autoimmunity: molecular interactions and therapeutic implications. (1990) (3)
β-Amyloid: Enemy or Remedy? (2012) (3)
Muscle ® bres and cultured muscle cells express the B 7 . 1 / 2-related inducible co-stimulatory molecule , ICOSL : implications for the pathogenesis of in ̄ ammatory myopathies (2003) (3)
[Monoclonal antibodies improve therapy of relapsing multiple sclerosis. Molecular basis and clinical results of anti-VLA4 (natalizumab) therapy]. (2006) (3)
Alemtuzumab and Multiple Sclerosis: Another Note of Caution. (2016) (3)
The prospects for neuroprotection in MS. (Editorial) (2003) (3)
Chapter 53 – Multiple Sclerosis (2003) (3)
Neurotrophic factors protect myelin from attack. (2003) (3)
Immune responses in muscle (1992) (3)
[2012: Update on diagnosis and treatment of multiple sclerosis]. (2012) (3)
[Current aspects of therapy conversion for multiple sclerosis]. (2015) (3)
[Blocking adhesion molecules with natalizumab in multiple sclerosis]. (2005) (3)
Extracellular matrix in multiple sclerosis lesions: Induction of fibrillar collagens, biglycan, and decorin in association with infiltrating immune cells (2008) (2)
Progress in understanding inflammatory and autoimmune diseases of the central nervous system (2009) (2)
[Cannabinoids in multiple sclerosis. Opportunity or hazard?]. (2004) (2)
[Immunogenetics of myasthenia gravis]. (1983) (2)
Physiochemical and immunological properties of acetylcholine receptors from human muscle (1984) (2)
Review T-Cell-Mediated Autoimmunity Novel Techniques to Characterize Autoreactive T-Cell Receptors (2003) (2)
[Multiple sclerosis: updates on pathogenesis and treatment: report from the 9th MS Symposium held by the German Multiple Sclerosis Society]. (2011) (2)
Cannabinoids in multiple sclerosis. Opportunity or threat (2004) (2)
Human T cell autoimmunity against myelin basic protein: CD4+ cells recognizing epitopes of the T cell receptor beta chain from a myelin basic protein-specific T cell clone. (1993) (2)
Multiple sclerosis therapy: new agents carry new risks (2006) (2)
Use of Anti‐Interferon Beta Antibody Measurements in Multiple Sclerosis (2010) (2)
TNFRSF1A in multiple sclerosis (2013) (2)
[Interferon therapy of multiple sclerosis. A question of the correct dose?]. (2001) (2)
Neuroprotection in multiple sclerosis report from the MS Forum 16th Modern Management Workshop, March 2004, Cernobbio, Italy. (2004) (2)
Natalizumab-induced PML: can the beast be tamed? (2013) (2)
Immune dysbalance in childhood multiple sclerosis: a 'chicken or the egg' conundrum. (2019) (2)
[Progressive multifocal leukoencephalopathy. Undesirable side effect of immunotherapy]. (2009) (2)
Myasthenia gravis (1999) (2)
[Suspected multiple sclerosis]. (2006) (2)
Regulatory T cells in myositis — Good Samaritans at the site of inflammation? (2010) (2)
Faculty Opinions recommendation of A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. (2010) (2)
The basis of immunotherapy in neurological disease (2002) (2)
[Diagnosis and treatment of multiple sclerosis. Update, 2003]. (2003) (2)
Type III Systemic Allergic Reaction to Natalizumab—Reply (2008) (2)
Neurodegeneration, neuroprotection, glial cells, and myelin in multiple sclerosis (2007) (2)
The Role of Cytotoxic Effector Molecules and Cytokines in Inflammatory Myopathies (2002) (2)
[Formation of neutralizing antibodies in therapy of multiple sclerosis with interferon beta-1b. Practical procedure in suspected therapeutic failure]. (1997) (2)
[Interferon therapy of multiple sclerosis. Synopsis of various dosage forms]. (2004) (2)
Concurrent TNFRSF1A R92Q and pyrin E230K mutations in a child with multiple sclerosis (2010) (2)
Patient-to-patient transmission of natalizumab-associated PML? (2017) (2)
Cytokine-Based Therapeutics for Intrinsic CNS Disease Processes (2005) (1)
Differences in Antigen Expression on Normal Thymocytes and on Cells Derived from Hyperplastic Thymi and Thymoma of Myasthenia Gravis Patients (1984) (1)
Influence of ultraviolet radiation and diminished-function melanocortin 1 receptor variants on multiple sclerosis disease severity in two large multicenter cohort studies (2019) (1)
Multiple Sclerosis: New Immunobiologics (2007) (1)
What T-cell receptors can tell us about neurologic disease (2012) (1)
A clue for the enigmatic etiology? (2000) (1)
Aktuelle Therapie der multiplen Sklerose: Mitoxantron [Current therapy of multiple sclerosis: mitoxantrone] (1994) (1)
BAFF production in human brain by astrocytes: the central nervous system as a B cell fostering environment (2004) (1)
Myasthenia gravis: new therapeutic strategies. (1988) (1)
[Current therapy of multiple sclerosis: value of cyclosporin A and FK 506]. (1991) (1)
[Copolymer 1 in therapy of multiple sclerosis]. (1995) (1)
Myelin oligodendrocyte glycoprotein specific autoantibodies in adult patients with different inflammatory diseases of the CNS (2014) (1)
Immune checkpoint blockade for treating progressive multifocal leukoencephalopathy (2019) (1)
Effects of fingolimod treatment on astrocyte functions (2013) (1)
Multiple sclerosis (PP-038) (2010) (1)
Multiple sclerosis meets systems immunology (2021) (1)
Autoimmune diseases of muscle (1994) (1)
Intravenous immunoglobulins in MS: a panacea lacking approval? (2005) (1)
[Current therapy of multiple sclerosis. Are there indications for plasmapheresis?]. (1992) (1)
Early Initiation of Fingolimod Treatment Reduces the Recurrence of Disease Activity after Natalizumab Discontinuation in Multiple Sclerosis (P01.199) (2013) (1)
Fasciculations in lower motor neuron disease (1983) (1)
Disease course during pregnancy in patients with highly active multiple sclerosis (2016) (1)
[Multiple sclerosis: between wish and reality]. (2005) (1)
Multiple Sklerose – Revision der neuen McDonald-Diagnosekriterien (2006) (1)
Modulating microbiota: friend or foe? (2015) (1)
The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. (2000) (1)
Thymus in Thymoma-Associated Myasthenia Gravis (1997) (1)
ISNI 2012 Abstracts (2012) (1)
Antigen recognition properties of a Vgamma1.3Vdelta2-T-cell receptor from a rare variant of polymyositis. (2004) (1)
Stimulation of Autoimmune Helper T Lymphocytes from Patients with Myasthenia Gravis with Synthetic Peptides of the Acetylcholine Receptor Alpha Subunit a (1988) (1)
Interferon-beta 1a in der Therapie der schubförmigen multiplen Sklerose (1997) (1)
Pathogenic mechanisms of human autoantibodies against myelin oligodendrocyte glycoprotein (2017) (1)
[New approaches for the treatment of neurological diseases]. (2013) (1)
Modulation of sphingosine 1-phosphate signaling in neurologic disease (2011) (1)
Immunological basis for the therapy of multiple sclerosis. (1999) (1)
DNA Methylation Signatures of a Large Cohort Monozygotic Twins Clinically Discordant for Multiple Sclerosis (2018) (1)
A practicable method for the analysis of T lymphocyte subsets in CSF lymphopleocytosis (1983) (1)
[Multiple sclerosis: potential therapeutic options and update of ongoing studies]. (2004) (1)
[FTY720 (Fingolimod) as a new therapeutic option for multiple sclerosis]. (2007) (1)
In Vitro Propagation of Acetylcholine Receptor‐Specific Human T Lymphocytes with Autologous Epstein‐Barr Virus‐Transformed B Lymphocytes a (1987) (0)
Rapid Communication Induction ofHLA-DRExpression onHuman Myoblasts with Interferon-Gamma (1990) (0)
[Current therapy of multiple sclerosis: "T-cell vaccination"]. (1994) (0)
ADAM10 releases the immunoregulator soluble TACI — A novel biomarker for B-cell pathologies (2014) (0)
Target specificity of an autoreactive human  -T cell receptor in myositis* (2012) (0)
THE ROLE OF FIBROBLAST GROWTH FACTOR-9 IN CHRONICALLY DEMYELINATED MULTIPLE SCLEROSIS LESIONS (2011) (0)
New Genetic Links Between Alzheimer Disease and Immune-Mediated Diseases Revealed by Overlapping Genome-wide Association Study Hits (2017) (0)
Expression of HLA-G in inflammatory muscle diseases and myoblast culture (1998) (0)
[Current therapy of multiple sclerosis: are there indications for intravenous immunoglobulins?]. (1995) (0)
Immunotherapeutic Strategies for Multiple Sclerosis (2001) (0)
Finding cures for neurological diseases (2022) (0)
IgG synthesis within multiple sclerosis lesions correlates with local BAFF production (2008) (0)
First results of a prospective cohort study in clinically isolated syndromes and early multiple sclerosis of the German Competence Network Multiple Sclerosis (2015) (0)
Chapter 19 Future Therapies (2003) (0)
Akute demyelinisierende Enzephalomyelitis (ADEM) (1999) (0)
Anti-MOG autoantibodies in children with acute demyelination: Comparison of assays and longitudinal analysis (2011) (0)
[Current therapy of multiple sclerosis. Therapy with monoclonal antibodies to T-cell antigens (CD3, CD4, CD52)]. (1996) (0)
Fifth Meeting of the European Neurological Society (2004) (0)
Intracellular production of brain-derived neurotropbic factor (BDNF) in T-cells of healthy controls, untreated MS patients and interferon-beta treated MS patients before and after stimulation with PMA/ionomycin or interferon-beta (2004) (0)
Oral Presentations (2004) (0)
Quantification of cerebral hemodynamics in patients with multiple sclerosis: dynamic contrast-enhanced MRI in 3D at 3T (2011) (0)
[Neuroinflammatory diseases with a focus on multiple sclerosis - an overview]. (2013) (0)
Inflammatory Lesions (CD80) and B7.2 (CD86) In Vitro and in Costimulatory Molecule Distinct from B7.1 Human Muscle Cells Express a Functional (1998) (0)
Retromer Sorting A Pathogenic Pathway in Late-Onset Alzheimer Disease (2008) (0)
MicroRNA profiles of different types of MS lesions (2008) (0)
Expression of a B7-family protein distinct from B7.1 and B7.2 (1998) (0)
Gamma-delta T cells (WS-094) Chairpersons: Yoshimasa Tanaka, Marc Bonneville (2010) (0)
[B lymphocytes: a new "target" in treatment for multiple sclerosis]. (2009) (0)
[Corticosteroid therapy in multiple sclerosis. Comment on the letter by M. Haupts et al]. (1994) (0)
IMMUNOLOGICAL AND INFLAMMATORY DISORDERS OF THE CENTRAL NERVOUS SYSTEM. (1999) (0)
Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid (2015) (0)
Antigen-dependent HLA-DR-restricted lysis of human astrocytes by CD4+ T-cell lines specific for myelin-basic protein (MBP) (1991) (0)
The effect of a combined mitoxantrone and methylprednisolone therapy in primary compared to secondary progressive multiple sclerosis – an interim analysis after five years (2004) (0)
[Tumor necrosis factor and multiple sclerosis]. (1992) (0)
[Multiple sclerosis and retroviruses: new findings]. (1990) (0)
Stimulation of autoimmune helper T-lymphocytes from myasthenia gravis patients with synthetic peptides of the acetylcholine receptor alpha subunit (1987) (0)
Germany (2005) (0)
An animal model for paraneoplastic encephalitis (2004) (0)
Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis – an interim analysis after five years (2004) (0)
CURING MS: How science is solving the mysteries of multiple sclerosis By Howard L. Weiner 2004. New York: Crown Publishers. Price $24.95 ISBN 0-609-60900-9 (2005) (0)
A reliable method for immunocytochemical characterization of CSF cells (1987) (0)
[Progress of therapy in patients with multiple sclerosis]. (2010) (0)
Stop inflammation and you stop neurodegeneration in MS – Commentary (2017) (0)
Multiple sclerosis (WS-038) Chairpersons: Jyun-ichi Kira, Richard Ransohoff (2010) (0)
Antigen-specific tolerance induction by transcriptional targeting of dendritic cells with a novel lentiviral vector (2008) (0)
Gene expression analysis in formalin fixed and paraffin embedded (FFPE) vs. frozen samples from multiple sclerosis patients and controls (2008) (0)
Interferon beta-1b in multiple sclerosis - A seminar-in-print - Questions and answers (1996) (0)
Mesenchymal stem cells for multiple sclerosis: hype or hope? (2021) (0)
[Status and perspectives in the therapy of multiple sclerosis. A. Multiple sclerosis; the facts]. (1997) (0)
B lineage cells in inflammatory central nervous system - Reply (2006) (0)
[Therapy of multiple sclerosis]. (1999) (0)
Toward identification of personalized immunological profiles in multiple sclerosis. (2022) (0)
Chapter 8. Use of Anti-Interferon Beta Antibody Measurements in Multiple Sclerosis (2008) (0)
Faculty Opinions recommendation of Transgenic labeling of the corticospinal tract for monitoring axonal responses to spinal cord injury. (2006) (0)
Anti-nicotinic receptor autoimmunity in myasthenia gravis. Establishment of specific T-helper cell lines and identification of sensitizing epitopes on the alpha-subunit. (1988) (0)
A protocol for characterizing T-cell receptors from human histological specimens and for identifying their antigens. (2006) (0)
Natalizumab as New Therapeutic Option for Multiple Sclerosis (2008) (0)
Tissue-resident CD8+ memory T cells in multiple sclerosis. (2020) (0)
Correction: Broader Epstein–Barr virus–specific T cell receptor repertoire in patients with multiple sclerosis (2022) (0)
Myasthenia gravis measurement of anti achr antibodies using achr from the cell line te671 (1991) (0)
Risk Factors for Relapses After Switching From Natalizumab To Fingolimod (P7.241) (2014) (0)
Oligodendrocyte myelin glycoprotein as a novel target for pathogenic autoimmunity in the CNS (2020) (0)
ENS Communications (2001) (0)
Eleventh meeting of The European Neurological Society21–25 April, 2001, Paris, France (2001) (0)
Antibody Therapies for Progressive Multiple Sclerosis and for Promoting Repair (2022) (0)
Contactin-2/TAG-1 directed autoimmunity is identified in MS patients and mediates gray matter pathology in EAE (2008) (0)
Exome Array GWAS in 10,000 Germans Identifies Association between MUC22 and Multiple Sclerosis (2015) (0)
Somatic hypermutation of intrathecal IgM-producing B cells in multiple sclerosis patients (2012) (0)
Neurofascin-specific Autoantibodies Mediate Axonal Injury in Inflammatory Demyelinating Diseases of the Central Nervous System (2007) (0)
[Current therapy of multiple sclerosis: mitoxantrone]. (1994) (0)
Identification of circulating MOG-specific B cells in patients with MOG antibodies (2020) (0)
Multiple sclerosis and subclinical neuropathology in healthy individuals with familial risk: A scoping review of MRI studies (2021) (0)
Concurrent TNFRSF 1 A R 92 Q and pyrin E 230 K mutations in a child with multiple sclerosis (2010) (0)
[Immunotherapy of multiple sclerosis. Consensus and controversies]. (1999) (0)
[Multiple sclerosis: can therapy delay ongoing disability?]. (2011) (0)
Secondary cerebrovenous outflow in relation to duration of disease in patients with multiple sclerosis (2012) (0)
[Neurology. Therapeutic advances through systems research and molecular biology]. (1999) (0)
[Interferon-beta 1a in therapy of relapsing-remitting multiple sclerosis]. (1997) (0)
Rituximab: eine Therapieoption bei Neuromyelitis optica? (2009) (0)
Tumor immune therapy targeted against on coneuronal antigens: might this approach induce encephalomyelitis? (2001) (0)
Polymyositis. (1992) (0)
[Neurology 2000. From the molecule to the system]. (1999) (0)
Retromer SortingA Pathogenic Pathway in Late-Onset Alzheimer Disease (2008) (0)
Cover Picture: Eur. J. Immunol. 8/09 (2009) (0)
DNA methylation signatures of monozygotic twins clinically discordant for multiple sclerosis (2019) (0)
Neurological manifestations in autoinflammatory syndromes: a series of 131 patients from our neuroimmunology departement (2015) (0)
The homeostatic chemokine CCL19 is constitutively expressed in the CNS, up-regulated in multiple sclerosis lesions, and is correlated with intrathecal IgG production (2006) (0)
Interdisziplinäres Risikomanagement in der Therapie der multiplen Sklerose (2016) (0)
Optical coherence tomography (OCT) pattern in myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies positive patients: characterised by severe optic neuritis and subclinical retinal axonal degeneration (2016) (0)
Astrocytes trigger neurodegeneration through nitric oxide release after TrkB engagement: Implications for multiple sclerosis (2012) (0)
Effect of early initiation or switch to fingolimod on relapse outcomes in patients with relapsing-remitting multiple sclerosis: Pooled analysis from Phase 3 and Real-World studies (2017) (0)
["Fatigue" in multiple sclerosis]. (2000) (0)
PW02-032 - CNS manifestations and NLRP3/CIAS1 gene mutations (2013) (0)
Transcript profiling of different types of multiple sclerosis lesions yields FGF1 as a promoter of remyelination (2014) (0)
Soluble TNFα receptor (p55)-1gG inhibits proliferation of human T-cell lines in vitro. Implications for multiple sclerosis therapy (1995) (0)
Immune Cells Ligands and Their Receptors on Human Line-Derived Neurotrophic Factor Family Expression and Function of Glial Cell (2005) (0)
Faculty Opinions recommendation of Clonal expansions of CD4+ B helper T cells in autoimmune myasthenia gravis. (2007) (0)
IN VITRO SELECTION OF RAT AUTOIMMUNE HELPER T‐LYMPHOCYTES SPECIFIC FOR ACETYLCHOLINE RECEPTOR (AChR) (1981) (0)
Interferontherapie der Multiplen Sklerose (2004) (0)
clinical implications of basic research Molecular Mimicry in Multiple Sclerosis (2003) (0)
Maintenance of B cells and plasma cell in the CNS in multiple sclerosis (2008) (0)
Chapter 38. Cerebral Vasculitis (2008) (0)
Measurement of anti-acetylcholine receptor antibodies using the cell line TE671 (1991) (0)
Activation in Autoimmunity Released by ADAM10 and Reflects B Cell The Immunoregulator Soluble TACI Is (2014) (0)
Explorative study of emerging blood biomarkers in progressive multiple sclerosis (EmBioProMS) (2350) (2020) (0)
Trans-species activation of a myelin basic protein (MBP)-specific human T cell clone using APC from MHC-compatible rhesus monkeys (1994) (0)
Reply (2006) (0)
[Myasthenia gravis. Prototype of an anti-receptor autoaggression disease (author's transl)]. (1981) (0)
Abstracts of the Symposia (2006) (0)
[Current therapy of multiple sclerosis. Oral tolerance induction to myelin antigens]. (1993) (0)
Review of Novel Immunotherapeutic Strategies for MS (2007) (0)
[Betaferon and therapy of multiple sclerosis--present and future]. (2001) (0)
[Current therapy of multiple sclerosis--high-dose intravenous therapy with corticosteroids]. (1992) (0)
Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study (2019) (0)
[Bone marrow and stem cell transplantation in multiple sclerosis?]. (1999) (0)
Fingolimod induces neuroprotective factors in human astrocytes (2015) (0)
Subclinical concordance rate in monozygotic twins clinically discordant for multiple sclerosis. (2016) (0)
Perforin expression in polymyositis and other inflammatory muscle diseases (1994) (0)
Identi cation and temporal stability of conformational epitopes of autoantibodies against Myelin Oligodendrocyte Glycoprotein recognized by patients with di erent in ammatory central nervous system diseases (2014) (0)
New tools for investigating the immunopathogenesis of MS: Principles and applications (2008) (0)
[Analysis of surface markers on cerebrospinal fluid-producing cells. Contribution to the differential diagnosis of intrathecal lymphomas]. (1984) (0)
Altered grey matter networks in young patients with MS at genetic risk for Alzheimer's disease (2017) (0)
[Multiple sclerosis. Therapeutic nihilism is the wrong approach here]. (2002) (0)
T cell transformation byHerpesvirus saimiri: Immortalized cells from human and rhesus monkey share essential properties (2007) (0)
T cell receptor immunotherapy in multiple sclerosis? Human T cell lines recognizing peptide analogs of T cell receptor β chains from MBP specific autologous T cell clones (1991) (0)
Twin study reveals non-heritable immune perturbations in multiple sclerosis (2022) (0)
Anti-CD20 B-Cell Depletion Increases the Frequency of Regulatory T Cells, but Enhances Monocyte Reactivity in Multiple Sclerosis and Neuromyelitis Optica (2011) (0)
Soluble BCMA is shed from B cells by gamma-secretase, functions as APRIL-specific decoy and reflects intrathecal Ig-production in multiple sclerosis (2014) (0)
IN24-TU-01 Immunological and neurobiological interactions in multiple sclerosis (2009) (0)
Model of myasthenia gravis using human thymus tissue transplanted into SCID mice (1991) (0)
Nervous System Diseases Central Patients with Different Inflammatory Oligodendrocyte Glycoprotein Recognized by Conformational Epitopes on Myelin Distinction and Temporal Stability of (2013) (0)
Molecular characterization of paired immunoglobulin heavy and light chains of clonally expanded antibodies in the presence of a strong polyclonal background (2017) (0)
MRI, Big Data, and Artificial Intelligence (2021) (0)
[Does interferon beta slow the progression of multiple sclerosis? Long-term effect of IFN-β on progression of physical disability is still not proven]. (2012) (0)
T cell receptors of “mucosal-associated invariant T” cells in multiple sclerosis brain lesions (2014) (0)
Principles of Immunomodulatory Therapy (1994) (0)
010 Radio-immunoprecipitation-assay for acetylcholine-receptor antibodies using cell line TE671 (1992) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Reinhard Hohlfeld?

Reinhard Hohlfeld is affiliated with the following schools:

Reinhard Hohlfeld's Academic­Influence.com Rankings

Why Is Reinhard Hohlfeld Influential?

Reinhard Hohlfeld's Published Works

Published Works

What Schools Are Affiliated With Reinhard Hohlfeld?

Reinhard Hohlfeld's AcademicInfluence.com Rankings